-
2/16/2018
The manuscript of Dr. Lyne Gagnon et al. examines PBI-4050's ligand affinity in vitro and in vivo for the fatty acid receptors, GPR40 and GPR84.
-
1/29/2018
ProMetic Life Sciences announces today the outcome of a successful clinical development Type C meeting with the FDA for its orally active anti-fibrotic lead drug candidate, PBI-4050.
-
12/19/2017
ProMetic announced today that an orphan drug designation status has been granted to its Plasminogen for the treatment of IPF by the FDA.
-
12/11/2017
ProMetic Life Sciences announced today that its orally-active drug candidate, PBI-4050, has been issued a Promising Innovative Medicine designation by the UK MHRA as add-on treatment to nintedanib in patients with idiopathic pulmonary fibrosis.
-
11/14/2017
Total revenues for the third quarter ended September 30, 2017 were $24M compared to $3.7M for the third quarter ended September 30, 2016.
-
10/25/2017
Prometic today announced that the FDA has granted Fast Track designation to PBI-4050, a clinical candidate in development for IPF.
-
10/23/2017
Prometic today announces in vivo data from compounds PBI-4050 and PBI-4547 for the prevention and treatment of liver diseases, and associated metabolic syndrome are being presented in three poster sessions at AASLD.
-
9/25/2017
-
9/19/2017
-
8/15/2017
-
8/14/2017
-
6/12/2017
-
5/23/2017
-
4/20/2017
-
4/18/2017
-
3/31/2017
-
3/30/2017
-
3/3/2017
-
2/22/2017
-
-
-
1/18/2017
-
11/17/2016
-
11/16/2016
-
11/15/2016
-
11/14/2016
-
10/20/2016
-
10/12/2016
-
6/9/2016
-
5/25/2016
-
5/18/2016
-
5/13/2016
-
5/12/2016
-
4/14/2016
-
3/31/2016
-
3/22/2016
-
3/15/2016
-
3/3/2016
-
3/1/2016
-
12/1/2015
-
-
11/21/2014
-
11/11/2014